Diabetes Mellitus Science

Ultra-fast acting insulin analogs: superiority in the treatment of diabetes type 1 and type 2. A review
14-11-2025Ultra-fast acting insulin analogs were created to achieve a physiological profile of action with more rapid and pronounced initial insulin peak. The accelerated absorption of ultra-fast-acting insulin analogues results in a more rapid onset of action, with insulin concentrations reaching their peak in the bloodstream earlier compared to rapid-acting insulin analogues. This rapid peak of insulin action better matches the postprandial glucose absorption profile, resulting in improved glycemic...

Type 2 diabetes mellitus in rheumatoid arthritis and systemic lupus erythematosus: A review
14-11-2025Immunoinflammatory rheumatic diseases (IIRD), such as rheumatoid arthritis and systemic lupus erythematosus, are characterized by common mechanisms of development and similar comorbid pathology, including diabetes mellitus (DM) type 2. Patients with IIRD with concomitant DM represent one of the most difficult groups to manage due to serious complications and forced polypharmacy. The article considers risk factors for carbohydrate metabolism disorders, both traditional and directly associated...

Aggressive course of ectopic ACTH syndrome due to adrenal medulla hyperplasia. Case report
14-11-2025The article presents a description of a clinical case of an ectopic focus of adrenocorticotropic hormone (ACTH) hypersecretion located in the adrenal medulla in a 64-year-old obese woman without other characteristic clinical signs of hypercorticism, with complaints of rapidly progressing lower limb edema, severe muscle weakness, loss of appetite, weight loss by 4 kg, as well as stage 2 arterial hypertension and type 2 diabetes mellitus. The patient's blood biochemistry showed severe hypokalemia,...

The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes
14-11-2025CONCLUSION: AntiAGE-Biom probiotic helps to maintain metabolic control and significantly improve body composition in T2D patients with initial HbA(1c)<7.5%.

The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
14-11-2025The rates of increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity in the world are steadily increasing and exceed even the wildest forecasts, which forces specialists to seek, develop and implement more effective therapeutic methods for these two interrelated non-communicable pandemics. This article discusses promising areas in the pharmacotherapy of obesity and T2DM with an emphasis on the development of a class of incretin hormone receptor agonists. Monoagonists...